What Should Patients Know about Antiphospholipid Antibodies and Antiphospholipid Syndrome? View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2012-03-20

AUTHORS

Doruk Erkan , Lindsay Lally , Michael D. Lockshin

ABSTRACT

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder in which the immune system makes antibodies (antiphospholipid antibodies or aPL) that increase the risk to form blood clots. The most commonly used tests to detect aPL are Lupus Anticoagulant test, Anticardiolipin Antibody Test, and Anti-Beta-2-gylycoprotein-I Test. Among the various manifestations of APS, the most common clinical problems are blood clots in the veins of the legs, strokes, and miscarriages. Antiphospholipid antibodies can occur in otherwise healthy individuals or in patients with other autoimmune disorders such as systemic lupus erythematosus (SLE). Having a positive aPL test does not mean the person has APS; 30–40% of SLE patients may have aPL, but only a small percentage develop APS. For all aPL-positive patients with or without SLE, whether or not they have had a blood clot in the past, the first essential step in the management is understanding the risk of thrombosis and eliminating reversible risk factors known to increase risk of clotting. Further management of aPL-positive patients depends on the individual patient, his or her aPL-related clinical manifestations, and additional medical conditions. More... »

PAGES

295-309

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_20

DOI

http://dx.doi.org/10.1007/978-1-4614-3194-7_20

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051665488


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Erkan", 
        "givenName": "Doruk", 
        "id": "sg:person.0706272321.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706272321.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.239915.5", 
          "name": [
            "Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lally", 
        "givenName": "Lindsay", 
        "id": "sg:person.01353036251.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353036251.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lockshin", 
        "givenName": "Michael D.", 
        "id": "sg:person.01215046705.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215046705.41"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2012-03-20", 
    "datePublishedReg": "2012-03-20", 
    "description": "Antiphospholipid syndrome (APS) is a systemic autoimmune disorder in which the immune system makes antibodies (antiphospholipid antibodies or aPL) that increase the risk to form blood clots. The most commonly used tests to detect aPL are Lupus Anticoagulant test, Anticardiolipin Antibody Test, and Anti-Beta-2-gylycoprotein-I Test. Among the various manifestations of APS, the most common clinical problems are blood clots in the veins of the legs, strokes, and miscarriages. Antiphospholipid antibodies can occur in otherwise healthy individuals or in patients with other autoimmune disorders such as systemic lupus erythematosus (SLE). Having a positive aPL test does not mean the person has APS; 30\u201340% of SLE patients may have aPL, but only a small percentage develop APS. For all aPL-positive patients with or without SLE, whether or not they have had a blood clot in the past, the first essential step in the management is understanding the risk of thrombosis and eliminating reversible risk factors known to increase risk of clotting. Further management of aPL-positive patients depends on the individual patient, his or her aPL-related clinical manifestations, and additional medical conditions.", 
    "editor": [
      {
        "familyName": "Erkan", 
        "givenName": "Doruk", 
        "type": "Person"
      }, 
      {
        "familyName": "Pierangeli", 
        "givenName": "Silvia S.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4614-3194-7_20", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4614-3193-0", 
        "978-1-4614-3194-7"
      ], 
      "name": "Antiphospholipid Syndrome", 
      "type": "Book"
    }, 
    "keywords": [
      "systemic lupus erythematosus", 
      "aPL-positive patients", 
      "antiphospholipid syndrome", 
      "blood clots", 
      "antiphospholipid antibodies", 
      "autoimmune disorders", 
      "aPL-related clinical manifestations", 
      "manifestations of APS", 
      "positive aPL test", 
      "reversible risk factors", 
      "systemic autoimmune disorders", 
      "lupus anticoagulant test", 
      "common clinical problem", 
      "additional medical conditions", 
      "risk of thrombosis", 
      "anticardiolipin antibody test", 
      "SLE patients", 
      "lupus erythematosus", 
      "clinical manifestations", 
      "risk factors", 
      "further management", 
      "aPL tests", 
      "medical conditions", 
      "individual patients", 
      "antibody test", 
      "clinical problem", 
      "healthy individuals", 
      "patients", 
      "immune system", 
      "clots", 
      "antibodies", 
      "syndrome", 
      "risk", 
      "disorders", 
      "manifestations", 
      "small percentage", 
      "APL", 
      "erythematosus", 
      "thrombosis", 
      "miscarriage", 
      "stroke", 
      "first essential step", 
      "test", 
      "vein", 
      "management", 
      "leg", 
      "persons", 
      "percentage", 
      "individuals", 
      "factors", 
      "essential step", 
      "conditions", 
      "system", 
      "step", 
      "past", 
      "problem", 
      "Anticoagulant test", 
      "Anti-Beta-2-gylycoprotein"
    ], 
    "name": "What Should Patients Know about Antiphospholipid Antibodies and Antiphospholipid Syndrome?", 
    "pagination": "295-309", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051665488"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4614-3194-7_20"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4614-3194-7_20", 
      "https://app.dimensions.ai/details/publication/pub.1051665488"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-01-01T19:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/chapter/chapter_228.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4614-3194-7_20"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_20'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_20'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_20'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_20'


 

This table displays all metadata directly associated to this object as RDF triples.

140 TRIPLES      23 PREDICATES      83 URIs      76 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4614-3194-7_20 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 schema:author Nc6f294111a8a419594bdd1161855faa9
4 schema:datePublished 2012-03-20
5 schema:datePublishedReg 2012-03-20
6 schema:description Antiphospholipid syndrome (APS) is a systemic autoimmune disorder in which the immune system makes antibodies (antiphospholipid antibodies or aPL) that increase the risk to form blood clots. The most commonly used tests to detect aPL are Lupus Anticoagulant test, Anticardiolipin Antibody Test, and Anti-Beta-2-gylycoprotein-I Test. Among the various manifestations of APS, the most common clinical problems are blood clots in the veins of the legs, strokes, and miscarriages. Antiphospholipid antibodies can occur in otherwise healthy individuals or in patients with other autoimmune disorders such as systemic lupus erythematosus (SLE). Having a positive aPL test does not mean the person has APS; 30–40% of SLE patients may have aPL, but only a small percentage develop APS. For all aPL-positive patients with or without SLE, whether or not they have had a blood clot in the past, the first essential step in the management is understanding the risk of thrombosis and eliminating reversible risk factors known to increase risk of clotting. Further management of aPL-positive patients depends on the individual patient, his or her aPL-related clinical manifestations, and additional medical conditions.
7 schema:editor Ne8f3a33feaf241579960cbe1910b096f
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf N70d20b46e70d431583c977842fabd04a
12 schema:keywords APL
13 Anti-Beta-2-gylycoprotein
14 Anticoagulant test
15 SLE patients
16 aPL tests
17 aPL-positive patients
18 aPL-related clinical manifestations
19 additional medical conditions
20 antibodies
21 antibody test
22 anticardiolipin antibody test
23 antiphospholipid antibodies
24 antiphospholipid syndrome
25 autoimmune disorders
26 blood clots
27 clinical manifestations
28 clinical problem
29 clots
30 common clinical problem
31 conditions
32 disorders
33 erythematosus
34 essential step
35 factors
36 first essential step
37 further management
38 healthy individuals
39 immune system
40 individual patients
41 individuals
42 leg
43 lupus anticoagulant test
44 lupus erythematosus
45 management
46 manifestations
47 manifestations of APS
48 medical conditions
49 miscarriage
50 past
51 patients
52 percentage
53 persons
54 positive aPL test
55 problem
56 reversible risk factors
57 risk
58 risk factors
59 risk of thrombosis
60 small percentage
61 step
62 stroke
63 syndrome
64 system
65 systemic autoimmune disorders
66 systemic lupus erythematosus
67 test
68 thrombosis
69 vein
70 schema:name What Should Patients Know about Antiphospholipid Antibodies and Antiphospholipid Syndrome?
71 schema:pagination 295-309
72 schema:productId Nb7b82e46d5ec44cda4bc8d0f577d4eb5
73 Ndca77d15ae414e09b87aec3120df5099
74 schema:publisher N07a9b6992a8a4a35a677e69d1d00ebb0
75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051665488
76 https://doi.org/10.1007/978-1-4614-3194-7_20
77 schema:sdDatePublished 2022-01-01T19:13
78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
79 schema:sdPublisher N237fb6f2cb3e44479eecf56d6a8096c7
80 schema:url https://doi.org/10.1007/978-1-4614-3194-7_20
81 sgo:license sg:explorer/license/
82 sgo:sdDataset chapters
83 rdf:type schema:Chapter
84 N0029bc5e9b6e4ad5a29439cf845c963e schema:familyName Pierangeli
85 schema:givenName Silvia S.
86 rdf:type schema:Person
87 N0386de7bc85347b3942f70b0bc82b36d rdf:first N0029bc5e9b6e4ad5a29439cf845c963e
88 rdf:rest rdf:nil
89 N07a9b6992a8a4a35a677e69d1d00ebb0 schema:name Springer Nature
90 rdf:type schema:Organisation
91 N0e2d99cb1c41473a854e9dfe5dc2a863 rdf:first sg:person.01353036251.11
92 rdf:rest Nc11e435f70844d4c813901c5011809f5
93 N237fb6f2cb3e44479eecf56d6a8096c7 schema:name Springer Nature - SN SciGraph project
94 rdf:type schema:Organization
95 N70d20b46e70d431583c977842fabd04a schema:isbn 978-1-4614-3193-0
96 978-1-4614-3194-7
97 schema:name Antiphospholipid Syndrome
98 rdf:type schema:Book
99 Nb7b82e46d5ec44cda4bc8d0f577d4eb5 schema:name dimensions_id
100 schema:value pub.1051665488
101 rdf:type schema:PropertyValue
102 Nc11e435f70844d4c813901c5011809f5 rdf:first sg:person.01215046705.41
103 rdf:rest rdf:nil
104 Nc6f294111a8a419594bdd1161855faa9 rdf:first sg:person.0706272321.25
105 rdf:rest N0e2d99cb1c41473a854e9dfe5dc2a863
106 Ndca77d15ae414e09b87aec3120df5099 schema:name doi
107 schema:value 10.1007/978-1-4614-3194-7_20
108 rdf:type schema:PropertyValue
109 Nde4eed7dace341eaab984dfd84439212 schema:familyName Erkan
110 schema:givenName Doruk
111 rdf:type schema:Person
112 Ne8f3a33feaf241579960cbe1910b096f rdf:first Nde4eed7dace341eaab984dfd84439212
113 rdf:rest N0386de7bc85347b3942f70b0bc82b36d
114 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
115 schema:name Medical and Health Sciences
116 rdf:type schema:DefinedTerm
117 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
118 schema:name Immunology
119 rdf:type schema:DefinedTerm
120 sg:person.01215046705.41 schema:affiliation grid-institutes:grid.5386.8
121 schema:familyName Lockshin
122 schema:givenName Michael D.
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215046705.41
124 rdf:type schema:Person
125 sg:person.01353036251.11 schema:affiliation grid-institutes:grid.239915.5
126 schema:familyName Lally
127 schema:givenName Lindsay
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353036251.11
129 rdf:type schema:Person
130 sg:person.0706272321.25 schema:affiliation grid-institutes:grid.5386.8
131 schema:familyName Erkan
132 schema:givenName Doruk
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706272321.25
134 rdf:type schema:Person
135 grid-institutes:grid.239915.5 schema:alternateName Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
136 schema:name Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
137 rdf:type schema:Organization
138 grid-institutes:grid.5386.8 schema:alternateName The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA
139 schema:name The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA
140 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...